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Fanconi anemia (FA) is a rare genetic disease characterized by increased risk for bone 
marrow failure and cancer. The FA proteins function together to repair damaged 
DNA. A central step in the activation of the FA pathway is the monoubiquitination of 
the FANCD2 and FANCI proteins under conditions of cellular stress and during S-
phase of the cell cycle. The regulatory mechanisms governing S-phase 
monoubiquitination, in particular, are poorly understood. In this study, we have 
identified a CDK regulatory phospho-site (S592) proximal to the site of FANCD2 
monoubiquitination. FANCD2 S592 phosphorylation during S-phase was detected by 
LC-MS/MS and by immunoblotting with a S592 phospho-specific antibody.  Mutation 
of S592 disrupts S-phase and DNA damage-inducible monoubiquitination. In addition, 
FA-D2 (FANCD2-/-) patient cells expressing S592 mutants display reduced 
proliferation under conditions of replication stress and increased mitotic aberrations, 
including nucleoplasmic bridges and multinucleated cells. Our findings describe a 
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Protection of the integrity of our genome depends on the concerted activities of several 
DNA repair pathways that ensure the timely repair of DNA damage. These DNA 
repair pathways need to be tightly coordinated and regulated upon cellular exposure to 
exogenous DNA damaging agents, as well as during the cell cycle. Somatic disruption 
of the DNA damage response leads to mutation, genome instability and cancer. In 
addition, germline mutations in DNA repair genes are associated with hereditary 
diseases characterized by increased cancer risk and other clinical manifestations. 
Fanconi anemia (FA) is a rare genetic disease characterized by congenital anomalies, 
increased risk for bone marrow failure and cancer, and accelerated aging (Alter 2014; 
Ceccaldi, Sarangi, and D’Andrea 2016; Rosenberg, Greene, and Alter 2003). FA is 
caused by germline mutations in any one of 23 genes. The FA proteins function 
together in a pathway to repair damaged DNA and to maintain genome stability. A 
major role for the FA pathway in the repair of DNA interstrand crosslinks (ICLs) has 
been established (I Garcia-Higuera et al. 2001; Kim and D’Andrea 2012).  
The main activating step of the FA pathway is thought to be the 
monoubiquitination of the FANCD2-FANCI heterodimer (ID2), which is catalyzed by 
the FA-core complex, comprising FANCA, FANCB, FANCC, FANCE, FANCF, 
FANCG, FANCL, UBE2T/FANCT, and the FA associated proteins. 
Monoubiquitination occurs following exposure to DNA damaging agents and during 
S-phase of the cell cycle (I Garcia-Higuera et al. 2001; Taniguchi et al. 2002). 
Recently, it was discovered that the monoubiquitination of FANCD2 and FANCI 





Wang et al. 2019). Moreover, ubiquitinated ID2 (ID2-Ub) assembles into 
nucleoprotein filament arrays on double-stranded DNA (Tan et al. 2020). The 
monoubiquitination of FANCD2 is necessary for efficient interstrand crosslink repair, 
the maintenance of common fragile site stability and faithful chromosome segregation, 
events that are all crucial for genomic stability (Meetei et al. 2003; Nakanishi et al. 
2005; Vinciguerra et al. 2010). 
A DNA damage-independent role for the FA pathway during the cell cycle has 
been implicated in several studies. For example, FANCD2 promotes replication fork 
protection during S-phase and ensures the timely and faithful replication of common 
chromosome fragile sites (Howlett et al. 2005; Madireddy et al. 2016). FANCD2 has 
also been shown to be involved in mitotic DNA synthesis (MiDAS) during prophase 
and is present on the terminals of anaphase ultrafine bridges (Chan et al. 2009; 
Garribba et al. 2018; Vinciguerra et al. 2010). During the cell cycle FANCD2 
monoubiquitination is maximal during S-phase and minimal during M-phase 
(Taniguchi et al. 2002). FANCD2 and FANCI are phosphorylated by the ATR and 
ATM kinases following exposure to DNA damaging agents, promoting their 
monoubiquitination (Chen et al. 2015; G. P. H. Ho et al. 2006). However, in general, 
the function and regulation of FANCD2 and FANCI during the cell cycle remains 
poorly understood.  
Cyclin-dependent kinases (CDKs) play a major role in regulating cell cycle 
progression, with CDK-mediated hyperphosphorylation of the retinoblastoma protein 
(pRb) being the primary mechanism of cell cycle regulation (Adams et al. 1999; 





cycle. Several protein components of the homologous recombination repair (HR), 
translesion DNA synthesis (TLS), non-homologous end joining (NHEJ), and telomere 
maintenance pathways are CDK substrates (Wohlbold and Fisher 2009). For example, 
the BRCA2 protein is phosphorylated by CDK1 as cell progress towards mitosis. 
CDK-mediated phosphorylation of BRCA2 blocks interaction with RAD51 and 
thereby restricts homologous recombination DNA repair during M-phase (Esashi et al. 
2005; Yata et al. 2014).  Conversely, CDK1/2 phosphorylate the EXO1 nuclease to 
promote DNA strand resection and homologous recombination repair during S-phase 
(Tomimatsu et al. 2014). 
In this study we have examined the regulation of the FANCD2 protein by 
phosphorylation, specifically during the cell cycle. We show that FANCD2 is 
phosphorylated on S592, a putative CDK site, during S-phase but not during M-phase 
and is phosphorylated by CDK2-Cyclin A in vitro. Mutation of S592 as well as CDK 
inhibition disrupts S-phase FANCD2 monoubiquitination. Furthermore, we 
demonstrate that FA-D2 patient cells stably expressing FANCD2 mutated at S592 
display reduced growth in the presence of DNA damaging agents, an altered cell cycle 
profile, and increased genomic instability manifested as increased micronuclei, mitotic 
bridges, and aneuploidy. Our results provide further mechanistic insight into the 








FANCD2 is phosphorylated under unperturbed conditions and during S-phase of 
the cell cycle  
To study the phosphorylation of the FANCD2 protein in the absence and presence of 
DNA damaging agents, we performed a lambda-phosphatase assay with several cell 
lines following incubation in the absence or presence of the DNA crosslinking agent 
mitomycin C (MMC). Notably, we observed a large increase in FANCD2 mobility 
following incubation of lysates with lambda-phosphatase even in the absence of MMC 
in all cell lines examined (Fig. 1A). These results suggest that FANCD2 is subject to 
extensive phosphorylation even in the absence of an exogenous DNA damaging agent. 
A similar change in protein mobility was not observed for FANCI (Fig. 1A). To 
determine if FANCD2 is subject to phosphorylation during the cell cycle, we 
performed a double thymidine block experiment causing an early S-phase arrest and 
analyzed phosphorylation at regular time points following release using the lambda-
phosphatase assay. We observed maximal phosphorylation of FANCD2 during S-
phase of the cell cycle, with much less phosphorylation observed as cells progressed 
through G2/M-and G1-phases of the cell cycle (Fig. 1B). Again, we observed no 
appreciable change in FANCI mobility upon lambda-phosphatase treatment, 
suggesting that FANCI is not subject to the same level of phosphorylation as 
FANCD2 during the cell cycle (Fig. 1B). Similar findings were observed with U2OS 
cells (Fig. S1A and B). We also performed a M-phase arrest using nocodazole and 
again observed maximal levels of FANCD2 phosphorylation during S-phase (~15 h 





component of the FA core complex, a multi-subunit ubiquitin ligase that catalyzes the 
monoubiquitination of FANCD2 (I Garcia-Higuera et al. 2001; Irene Garcia-Higuera 
et al. 2000). FANCD2 and FANCI monoubiquitination are defective in the absence of 
FANCA (I Garcia-Higuera et al. 2001). To determine if FANCD2 phosphorylation 
was dependent on the presence of FANCA, we performed a lambda-phosphatase assay 
with asynchronous and early-S-phase synchronized FA-A (FANCA-/-) and FANCA-
complemented FA-A cells. S-phase FANCD2 phosphorylation was observed in the 
absence of FANCA, albeit to a slightly lesser extent than in cells FANCA-
complemented FA-A cells, suggesting that phosphorylation of FANCD2 is not strictly 
dependent on its ubiquitination (Fig. 1C). 
 
FANCD2 is a CDK substrate 
Phosphorylation of FANCD2 during the cell cycle suggested a role for cyclin-
dependent kinases (CDKs) in the regulation of FANCD2. CDKs phosphorylate serine 
or threonine residues in the consensus sequence [S/T*]PX[K/R], and several DNA 
repair proteins are known CDK substrates, including BRCA2, FANCJ, and CtIP 
(Esashi et al. 2005; Huertas and Jackason 2009; Nath and Nagaraju 2020). Both 
FANCD2 and FANCI have several putative CDK phosphorylation sites with varying 
degrees of conservation (Fig. S2A and B). To begin to assess the role of CDKs in the 
regulation of FANCD2, we performed a double-thymidine block in the absence and 
presence of the CDK inhibitors purvalanol A and SNS-032. At the concentrations 
tested in this experiment, treatment with both inhibitors resulted in a significant 





double-thymidine arrest and a modest reduction in FANCD2 phosphorylation (Fig. 
2A). Reduced FANCD2 phosphorylation was also observed upon incubation with 
other CDK inhibitors and upon short-term exposure to purvalanol A (Fig. S2C and D). 
To determine if FANCD2 is a CDK substrate, we immunoprecipitated FANCD2 from 
FA-D2 (FANCD2-/-) patient cells stably expressing V5-tagged LacZ or FANCD2 and 
probed immune complexes with a pan anti-pS/T-CDK antibody. An immune reactive 
band was detected in immune complexes from cells expressing FANCD2 and not 
LacZ (Fig. 2B), suggesting that FANCD2 is a CDK substrate. We also performed an 
in vitro CDK kinase assay with CDK2-Cyclin A and full length FANCD2 purified 
from High Five insect cells (van Twest et al. 2017). Low levels of CDK-mediated 
phosphorylation were observed even in the absence of CDK2-Cyclin A and 
phosphorylation increased markedly upon incubation with CDK2-Cyclin A for 30 min 
(Fig. 2C). These results indicate that FANCD2 is a CDK substrate and suggest that 
FANCD2 monoubiquitination may be coupled to CDK phosphorylation.  
 
FANCD2 is phosphorylated on S592 during S-phase of the cell cycle  
To map the in vivo sites of FANCD2 phosphorylation, we immunoprecipitated 
FANCD2 from asynchronous U2OS cells stably expressing 3xFLAG-FANCD2 under 
stringent conditions. Immunoprecipitated FANCD2 bands were combined and 
subjected to phosphoproteomic analysis using LC-MS/MS (Fig. 3A and B). Under 
these non-DNA damaging conditions, we observed the phosphorylation of multiple 
sites including the previously detected ATM/ATR phosphorylation sites S1401 and 





putative CDK site S592 (Table 1). To analyze the phosphorylation of FANCD2 during 
the cell cycle, we synchronized HeLa cells in M-phase using nocodazole, 
immunoprecipitated FANCD2 immediately upon release and at 15 h post-release and 
again performed phosphoproteomic analysis using LC-MS/MS (Fig. 3C-F). Under 
these conditions, we again detected phosphorylation of FANCD2 on S592 in S-phase 
of the cell cycle and not during M-phase synchronized cells suggesting that the 
phosphorylation of FANCD2 S592 might have an important regulatory function 
during S-phase (Fig. 3F). To study FANCD2 S592 phosphorylation more closely, we 
generated a S592 phospho-specific antibody. We arrested cells in M-phase using 
nocodazole and analyzed FANCD2 S592 phosphorylation upon release from 
nocodazole block. A FANCD2 pS592 immunoreactive band was observed at 12 h (S-
phase) following release (Fig. 3G), consistent with the results of our LC-MS/MS 
phosphoproteomic analysis (Fig. 3F, Table 1).  
 
Mutation of S592 disrupts FANCD2 monoubiquitination during S-phase and 
upon exposure to DNA damaging agents  
FANCD2 S592 localizes to a flexible loop proximal to K561, the site of 
monoubiquitination, suggest a potential ubiquitination regulatory function for S592 
phosphorylation (Fig. 4A). To begin to characterize the role of S592 phosphorylation, 
we generated phospho-dead (S592A) and phospho-mimetic (S592D) variants and 
stably expressed these in FA-D2 (FANCD2-/-) patient-derived cells. Mutation of S592 
did not overtly impact the stability or overall structure of FANCD2 as evidenced by 





(Fig. 4B). To analyze the effects of mutation of S592 on DNA damage-inducible 
FANCD2 monoubiquitination, we incubated cells in the absence and presence of 
mitomycin C (MMC) and analyzed FANCD2 monoubiquitination by immunoblotting. 
The FANCD2-S592A mutant showed similar levels of basal and MMC-inducible 
monoubiquitination compared to FANCD2-WT (Fig. 4B). However, basal levels of 
FANCD2-S592D monoubiquitination were elevated, and MMC-inducible FANCD2-
S592D monoubiquitination was reduced, compared to FANCD2-WT and FANCD2-
S592A (Fig. 4B). Under the same experimental conditions, we also examined levels of 
CDC2 pY15, which is an inhibitory mark of mitotic progression at the G2/M 
checkpoint of the cell cycle and is expected to increase upon DNA damage conditions. 
In cells expressing FANCD2-WT, we observed a robust increase in CDC2 pY15 
levels following MMC exposure. However, this increase was attenuated in the absence 
of FANCD2 and in cells expressing the FANCD2 S592 variants (Fig. 4B), suggestive 
of a defect in the mitotic checkpoint or mitotic progression.  
To analyze the effects of S592 mutation on S-phase FANCD2 
monoubiquitination (Taniguchi et al. 2002), cells were subject to a double thymidine 
block, and FANCD2 monoubiquitination was analyzed upon release. Compared to 
FANCD2-WT, S-phase monoubiquitination was markedly attenuated for both S592 
variants (Fig. 4C). We also analyzed levels of the mitotic marker H3 pS10 in these 
cells. Compared to cells expressing FANCD2-WT, we observed persistent levels of 
H3 pS10 in FA-D2 cells expressing empty vector and the FANCD2-S592A mutant 
(Fig. 4C). We observed a similar phenotype of elevated H3 pS10 in HeLa FANCD2-/- 





contrast to cells expressing empty vector and the FANCD2-S592A mutant, we 
observed a more rapid disappearance of H3 pS10 in cells expressing FANCD2-S592D 
(Fig. 4C). FACS analysis of FA-D2 patient cells expressing empty vector and the 
S592 variants upon release from double thymidine block indicated a higher percentage 
of cells in G2/M at earlier time points, compared to cells expressing FANCD2-WT 
(Fig. S3D). Taken together, these results demonstrate that mutation of FANCD2 S592 
disrupts S-phase monoubiquitination and leads to altered G2-M cell cycle progression.  
 
Mutation of FANCD2 S592 leads to decreased proliferative capacity and 
increased mitotic defects   
To assess the functional impacts of mutation of FANCD2 S592, we monitored the 
proliferation of FA-D2 patient cells stably expressing FANCD2-WT and the S592 
variants in the presence of low concentrations of DNA damaging agents for prolonged 
periods using the xCELLigence real time cell analysis system. The xCELLigence 
system enables the analysis of cellular phenotypic changes by continuously 
monitoring electrical impedance. Impedance measurements are displayed as the cell 
index, which provides quantitative information about the biological status of the cells, 
including cell number, cell viability, and cell morphology (Hamidi, Lilja, and Ivaska 
2017; Kho et al. 2015). Compared to cells expressing FANCD2-WT, cells expressing 
empty vector and the S592 variants exhibited reduced viability when cultured in the 
presence of the DNA polymerase inhibitor aphidicolin (APH) (Fig. 5A and S4A). In 
contrast, mutation of FANCD2 S592 had no impact on growth in the presence of low 





in the presence of the CDK1 inhibitor RO3306. CDK1 inhibition resulted in reduced 
cell proliferation in cells expressing FANCD2-WT and the S592A variant compared to 
cells expressing empty vector or the S592D variant (Fig. S4B and C).  
To test the effects of S592 mutation on cell division we looked at different 
types of cytogenetic markers under non-stressed conditions.  Micronuclei arise from 
chromosome fragments that fail to incorporate in daughter nuclei during mitosis and 
they are a well characterized marker of genomic instability. We counted at least 400 
cells and the presence of micronuclei was significantly higher in cells expressing 
mutation in S592 compared with cells expressing FANCD2-WT suggesting increasing 
genomic challenges after mutation in S592 (Fig 5B, S6C). We also looked at nuclear 
buds which are biomarker of elimination of repair complexes and amplified DNA 
(Fenech 2002; Fenech and Crott 2002). We found a statistically significant higher 
percent of nuclear buds in S592 mutant cell lines compared to cells expressing 
FANCD2-WT (Fig. 5B, S6B). A high number of binucleated cells in asynchronous 
populations suggest difficulties in cell division, and is consistent with that previously 
observed by Vinciguerra et al., 2010  (Vinciguerra et al. 2010). In addition 
multinucleated cells (>2 nucleus) are caused by multiplication of centrioles and can 
promote genomic instability (Duensing et al. 2009; Korzeniewski, Treat, and 
Duensing 2011) . We detected a significant higher percent of binucleated and 
multinucleated cells expressing the FANCD2-S592 variants compared to cells 
expressing FANCD2-WT (Fig. 5B, S6A-D). Together these increases in mitotic 
aberrations suggest that mutation in S592 is promoting mitotic defects and genomic 





To test cell division under DNA damage conditions we performed a 
micronucleus assay. We treated FA-D2 cells expressing WT and S592 mutant versions 
of FANCD2 with APH and MMC for 24 h followed by a cytochalasin B treatment to 
block cytokinesis. We counted at least 300 binucleated cells and we did not detect 
statistically significant differences in percentage of micronuclei in cells expressing 
FANCD2-S592 mutant versions and FANCD2-WT (Fig. S5 A, C). Next, we counted 
at least 400 cells and scored nuclear buds and multinucleated cells. We found a 
statistically significant increase in nuclear buds after treating with MMC in cells 
expressing FANCD2-S592D compared to WT (Fig. S5 A, D). There were no 
significant differences in number of multinucleated in cells expressing FANCD2-S592 
mutants and FANCD2-WT (Fig. S5 A, E). In addition, we looked at nucleoplasmic 
bridges (NPBs) which are caused by telomere end-fusion or defective DNA repair 
(Fenech 2002; Podrimaj-Bytyqi et al. 2018). We score at least 400 cells and detected a 
significant increase in NPBs after cytokinesis block under non-stressed conditions in 
cells expressing mutant FANCD2-S592 compared to cells expressing FANCD2-WT 
(Fig. S5 A-B). These results suggest that the effect of mutation of FANCD2 in S592 is 
stronger under non-stressed conditions than when adding DNA damage.  
 
DISCUSSION 
In this study, we have investigated the posttranslational regulation of the central FA 
pathway protein FANCD2 under unperturbed conditions. The majority of studies to 
date have focused on the posttranslational regulation of FANCD2 and FANCI 





Higuera et al. 2001; Ishiai et al. 2008). We have observed that FANCD2 undergoes 
extensive phosphorylation during the cell cycle and, in particular, during S-phase of 
the cell cycle. Notably, in contrast, FANCI - a FANCD2 paralog - does not appear to 
be subject to the same degree of phosphorylation during the cell cycle. We have also 
determined that FANCD2 is phosphorylated by CDK2 on S592 both in vivo and in 
vitro. Phosphoproteomic analysis of human and Xenopus FANCD2 expressed in insect 
cells, as well as FANCD2 immune complexes from S-phase, but not M-phase, 
enriched cell populations uncovered phosphorylation of S592. Previous studies have 
shown that FANCD2 is monoubiquitinated as cells traverse S-phase, and this has been 
shown to contribute to the protection of stalled replication forks from degradation 
(Schlacher, Wu, and Jasin 2012; Taniguchi et al. 2002). Here we show that mutation 
of S592, or CDK inhibition, markedly abrogates S-phase monoubiquitination, strongly 
suggesting that S592 phosphorylation primes FANCD2 for ubiquitination during S-
phase. Recent studies have established that the FANCL RING E3 ubiquitin ligase 
allosterically alters the active site of the UBE2T E2 ubiquitin-conjugating enzyme to 
promote site-specific monoubiquitination of FANCD2 (Chaugule et al. 2020). 
Specifically, FANCL binding to UBE2T exposes a basic triad of the UBE2T active 
site, promoting favorable interactions with a conserved acidic patch proximal to K561, 
the site of ubiquitination (Chaugule et al. 2020). We speculate that S592 
phosphorylation may also augment interaction with the basic active site of UBE2T. 
Alternatively, S592 phosphorylation may inhibit FANCD2 de-ubiquitination by USP1, 
in a manner similar to that previously reported for the FANCI S/TQ cluster (Cheung et 





Our studies further emphasize the critical nature of coordinated 
posttranslational modification of FANCD2. Several studies have previously 
established intricate dependent and independent relationships between FANCD2 
monoubiquitination and phosphorylation. For example, the ATM kinase 
phosphorylates FANCD2 on several S/TQ motifs following exposure to ionizing 
radiation, e.g. S222, S1401, S1404, and S1418 - phosphorylation of S1401 and S1404 
were also detected under unperturbed conditions in this study. While phosphorylation 
of S222 promotes the establishment of the IR-inducible S-phase checkpoint, S222 
phosphorylation and K561 monoubiquitination appear to function as independent 
events (Taniguchi et al. 2002). In contrast, phosphorylation of FANCD2 on T691 and 
S717 by the ATR kinase has been shown to be required for efficient FANCD2 
monoubiquitination (Andreassen, D’Andrea, and Taniguchi 2004; Gary P. H. Ho et al. 
2006). Phosphorylation of FANCD2 by CK2 in residues 882-889 decreases 
monoubiquitination of FANCD2 in the absence of DNA damaging agents (Lopez-
Martinez et al. 2019). 
Multiple studies have showed the coordination of the DNA damage response 
and the cell cycle. For example BRCA2 is phosphorylated by CDK2 on the carboxy-
terminus precluding RAD51 binding, this inactivates homologous recombination prior 
to mitosis (Esashi et al. 2005). In contrast, CDK1/2 phosphorylation of EXO1 
endonuclease  positively regulates DNA strand resection and homologous 
recombination repair during S-phase (Tomimatsu et al. 2014). Another example of 
positive regulation occurs by CDK phosphorylation of CtIP during S-phase triggering 





the C-terminus (H. Wang et al. 2013). This phosphorylation event describes a 
coordination between the DNA damage response and cell cycle.  
A role of FANCD2 during S-phase of the cell cycle is to assist replication 
through common fragile sites (CFS) (Howlett et al. 2005; Madireddy et al. 2016) . The 
presence of FANCD2 in CFS persist through mitosis where is involved in mitotic 
DNA synthesis (MiDAS) in prophase and in anaphase ultrafine bridges (Chan et al. 
2009; Özer et al. 2018; Vinciguerra et al. 2010).  Functional FANCD2 promotes 
faithful chromosomal segregation. Previous studies showed that cells lacking 
FANCD2 have increased cytokinesis failure and apoptosis in unperturbed conditions. 
In this study, mutation in S592 caused elevated levels of binucleated cells 
multinucleated cells, nuclear buds and micronuclei in the absence of DNA damaging 
agents. This increase in mitotic defects suggest that mutation in S592 alters normal 
FANCD2 function during the cell cycle. We propose that CDK-mediated 
phosphorylation of FANCD2 promotes monoubiquitination during S-phase. This 
allows FANCD2 to assist in the replication of common fragile sites. We proposed that 
S592 phosphorylation during S-phase needs to occur to facilitate FANCD2 function in 
replication and further roles in CFS stability during mitosis. Mutation of this phospho-
site disrupts FANCD2 role during CFS replication thus increasing genomic instability. 
This is translated to disturbances during cell division, causing non-disjunction and 
chromosome breakages. We propose that S592 phosphorylation of FANCD2 needs to 
be shut down at the onset of M-phase to promote FANCD2 de-ubiquitination during 
mitosis. This study increases the understanding of the regulation of FANCD2 during 







MATERIALS AND METHODS 
Cell culture and Generation of Mutant Cell Lines  
HeLa cervical carcinoma and U20S osteosarcoma cells were grown in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% v/v FBS, L-glutamine (2 
mM) and penicillin/streptomycin. HeLa D2-/- generated by CRISPR-Cas9 were 
provided by Martin Cohn at the University of Oxford. 293FT viral producer cells 
(Invitrogen) were cultured in DMEM containing 12% v/v FBS, 0.1 mM non-essential 
amino acids (NEAA), 1% v/v L-glutamine, 1 mM sodium pyruvate and 1% v/v 
penicillin/streptomycin. PD20 FA-D2 (FANCD2hy/-) patient cells were purchased 
from Coriell Cell Repositories (Catalog ID GM16633). These cells harbor a 
maternally inherited A-G change at nucleotide 376 that leads to the production of a 
severely truncated protein, and a paternally inherited missense hypomorphic (hy) 
mutation leading to a R1236H change (Timmers et al. 2001). PD20 FA-D2 cells were 
stably infected with pLenti6.2/V5-DEST (Invitrogen) harboring wild-type or mutant 
FANCD2 cDNAs. Stably infected cells were grown in DMEM complete medium 
supplemented with 2 μg/ml blasticidin.  
 
Immunoprecipitation 
FA-D2 cells stably expressing LacZ or V5-tagged  FANCD2, U2OS, and U2OS 
3xFLAG FANCD2 cells were lysed in Triton-X100 lysis buffer (50 mM Tris.HCl pH 





inhibitors (Roche), and 40 mM b-glycerophosphate) on ice for 15 min followed by 
sonication for 10 s at 10% amplitude using a Fisher Scientific Model 500 Ultrasonic 
Dismembrator. Anti-V5 or anti-FLAG-agarose were washed and blocked with 
NETN100 buffer (20 mM Tris-HCl pH 7.5, 0.1% NP-40, 100 mM NaCl, 1 mM 
EDTA, 1 mM Na3VO4, 1 mM NaF, protease inhibitors (Roche)) plus 1% BSA and 
the final wash and resuspension was done in Triton-X100 lysis buffer. Lysates were 
incubated with agarose beads at 4°C for 2 h with nutating. Agarose beads were then 
washed in Triton-X100 lysis buffer and boiled in 1× NuPAGE buffer (Invitrogen) and 
analyzed for the presence of proteins by SDS-PAGE and immunoblotting or stained 
using Colloidal Blue Staining Kit (Invitrogen) for mass spectrometry. 
 
Cell Cycle FANCD2 Immunoprecipitation  
S-phase and M-phase synchronized populations of HeLa cells were lysed in lysis 
buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 400 mM KCl, 0.2 mM EDTA, 20% 
glycerol, 0.1 mM DTT, 0.1% NP-40, 1 mM PMSF and complete protease inhibitors). 
100 units of benzonase was added per 100 µL of lysis buffer. Protein G magnetic 
beads (Dynabeads, Novex) were crosslinked with anti-FANCD2 (NB100-182, Novus 
Biologicals) antibody. An equal volume of no salt buffer (20 mM HEPES, pH7.9, 1.5 
mM MgCl2, 0.2 mM KCl, 0.2 mM EDTA, 0.1mM DTT, 0.1% NP-40, plus complete 
protease inhibitors) was added to 2 mg of whole cell lysate. Samples were 
resuspended in anti-FANCD2-bound beads rotating at 4°C for 4 h. Beads were washed 
in wash buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.2 mM KCl, 300 mM KCl, 





inhibitor). The samples were eluted in urea elution buffer (8 M urea, 1 mM Na3VO4, 
2.5 mM Na₂H₂P₂O, 1 mM b-glycerophosphate and 25 mM HEPES, pH 8.0). Silver 
staining was performed to visualize the IP and FANCD2 pulldown was confirmed by 
western blot. Samples were sent for mass spectrometry at the COBRE Center for 
Cancer Research Development Proteomics Core at Rhode Island Hospital.  
 
Lambda Phosphatase Assay 
Cells were harvested and pellets were split into two, lysed in either lambda 
phosphatase lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 1 
mM dithiothreitol, 2 mM MnCl2, 0.01% Brij35, 0.5% NP-40, and protease inhibitor) 
or lambda phosphatase buffer with the addition of phosphatase inhibitors, 2 mM 
Na3VO4 and 5 mM NaF for 15 min at 4 oC followed by sonication for 10 s at 10% 
amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. Whole-cell 
lysates were incubated with or without 30 U of lambda phosphatase per 10 U of PP1 
for 2 h at 30°C, or for the times indicated. Proteins were resolved on NuPage 3-8% 
w/v Tris-Acetate, 4-12% w/v Bis-Tris gels (Invitrogen) and transferred to 




For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v 
SDS, 50 mM Tris-HCl, 10 mM EDTA followed by sonication for 10 s at 10% 





Bis-Tris gels (Invitrogen) and transferred to polyvinylidene difluoride (PVDF) 
membranes. The following antibodies were used: rabbit polyclonal antisera against 
FANCD2 (NB100-182; Novus Biologicals), FANCI (A301-254A, Bethyl 
Laboratories), CHK1 pS345 (2345, Cell Signaling), anti-pSP-CDK (9477, Cell 
Signaling), FLAG (F7425, Sigma), cyclin A (SC751, Santa Cruz), Cdc2 pY15 (4539, 
Cell Signaling), H3 pS10 (9701, Cell Signaling), FANCD2 pS592 (Pacific Bio), V5 




The S592A and S592D cDNA were generated by site-directed mutagenesis of the wild 
type FANCD2 cDNA using the Quikchange Site-directed Mutagenesis Kit 
(Stratagene). The forward (FP) and reverse (RP) oligonucleotide sequences used are 
as follows: S592A FP 5′- 
CGGCAGACAGAAGTGAAGCACCTAGTTTGACCCAAG-3′; S592A RP 5′-
CTTGGGTCAAACTAGGTGCTTCACTTCTGTCTGCCG-3’; S592D FP 5’-
GGCGGCAGACAGAAGTGAAGATCCTAGTTTGACCCAAGAG-3’; and S592D 
RP 5’-CTCTTGGGTCAAACTAGGATCTTCACTTCTGTCTGCCGCC-3’. The full 
length FANCD2 cDNA sequences were TOPO cloned into the pENTR/D-TOPO 
(Invitrogen) entry vector, and subsequently recombined into the pLenti6.2/V5-DEST 
(Invitrogen) destination vector and used to generate lentivirus for the generation of 







Hela WT or Hela D2-/- generated by CRISPR-Cas9 were seeded in at a density of 2 x 
104 in chamber slides (Millicell EZ Slide, Millipore) overnight. Cells were treated 
with 100 nM MMC for 24 h and fixed in fixing buffer (4% w/v paraformaldehyde, 
2% w/v sucrose in PBS, pH 7.4) at 4°C for 10 min. Cells were permeabilized using 
0.3% v/v Triton-X in PBS for 10 min at room temperature. Cells were blocked in 
antibody dilution buffer (ADB, 5% v/v goat serum, 0.1% v/v NP-40 in PBS, pH 7.4) 
and then incubated with mouse-anti H3 pS10 (Cell si1:250) and rabbit-anti-FANCD2 
(1:250). Cells were washed with PBS and incubated in secondary goat-anti-mouse 
Alexa Fluor 594 (1:500, Thermo Fisher) and donkey-anti-rabbit Alexa Fluor 488 
(1:500, Thermo Fisher) in ABD for 1 h. Cells were washed in PBS and stained with 
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, Vector Laboratories). 
 
Generation of Lentiviral Particles 
5 x 106 293FT cells were seeded in 10 cm2 dishes in DMEM + 12% v/v FBS + 1% v/v 
L-glutamine + 1% v/v sodium pyruvate +2% v/v non-essential amino acids without 
antibiotics. 5mL of a mix of Opti MEM and Fugene 6 was added dropwise to the cells 
and then cells were incubated. A mixture of 9 µg of Virapower packaging mix and 3 
µg pLenti-6.2-vector in OptiMEM was added to the cells and incubated for 6-8 h. The 
supernatant was collected and filtered through a 45 µm filter. 
 





For early S-phase arrest, cells were synchronized by the double thymidine block 
method (Ma and Poon 2016). Cells (5.0 x 105) were seeded in 10 cm2 dishes and 
treated with 2 mM thymidine (226740050, Acros Organics) for 18 h. Cells were 
washed with PBS and released in thymidine-free media for 10 h following by a 
second incubation in 2 mM thymidine for 18 h. Cells were washed twice with 
phosphate-buffered saline (PBS) and released into DMEM + 15% FBS, L-glutamine, 
and penicillin/streptomycin. For M-phase arrest, cells were synchronized using the 
mitotic shake-off method. HeLa (7.5 x 105) cells were seeded in 10 cm2 dishes. Cells 
were treated with 100 ng/mL of nocodazole (SML1665, Sigma) at 80-90% 
confluency for 15 h. Mitotic cells were collected by the shake off method and/or re-
plated in nocodazole-free media for cell cycle progression analysis. For late G2-phase 
arrest, cells were synchronized by reversible inhibition of CDK1 (Vassilev 2006). 
Cells (7.5 x 105) were seeded in 10 cm2 dishes and treated with 6 µM R03306 (15149, 
Cayman Chemicals) for 16 h. Cells were washed with PBS and released in fresh 
media without CDK inhibitors.  
 
Cell Cycle Analysis by FACS 
Cells were resuspended in 0.1 mL PBS and fixed by adding 1 mL ice-cold ethanol and 
stored at -20oC until analysis. Cells were then washed in PBS and incubated in 0.3-0.5 
mL RNase solution (1x RNase) for 10 min at 37oC. Cells were then incubated on ice 
for 5-10 min in 50 μg/mL propidium iodide (Sigma). Cells were analyzed using a 
BD FACSVerse flow cytometer system. Cell cycle distributions were determined 






In-vitro CDK Phosphorylation Assay  
Purified FANCD2, pRb and CDK2/Cyclin A proteins were a generous gift from 
Andrew Deans at the University of Melbourne. In order to remove any previous 
phosphorylation 2 µg of protein were incubated with 100 U of lambda phosphatase, 
10 mM protein metallophosphatases (PMP) and 10 mM MnCl2 at 30oC for 30 min. 
Lambda phosphatase was then removed from the reaction using 30K columns. Protein 
was then resuspended in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, in preparation for 
the kinase reaction. For the phosphorylation reaction, each reaction tube was 
composed of the following reagents in this specific order: 10x CDK kinase buffer 
(250 mM Tris pH 7.5, 250 mM glycerophosphate, 50 mM EGTA, 100 mM MgCl2), 2 
µg of protein, 15, 30, 60, 100nM CDK2:Cyclin A, and 20 µM ATP. Samples were 
incubated at 30oC for 30 min and the reaction was stopped by adding 10 µL of 10% 
b-mercaptoethanol in 4x LDS buffer.  
 
Micronucleus Assay  
For micronuclei analysis, cells were seeded at a density of 2 x 104 in chamber slides 
(Millicell EZ Slide, Millipore) overnight. On the following day, cells were treated 
with 0.4 µM aphidicolin (APH) or 40 nM mitomycin C (MMC) for 24 h, then washed 
with PBS and treated with 4.5 µg/mL cytochalasin B (Sigma) for 24 h to inhibit 
cytokinesis. Cells were fixed in fixing buffer (4% w/v paraformaldehyde, 2% w/v 
sucrose in PBS, pH 7.4) at 4°C for 10 min. Permeabilization was performed using 





antibody dilution buffer (ADB, 5% v/v goat serum, 0.1% v/v NP-40 in PBS, pH 7.4) 
and then incubated with mouse-anti-tubulin (1:1,000, NeoMarkers) for 1 h in ADB, 
washed with PBS and incubated in secondary goat-anti-mouse Alexa Fluor 594 
(1:500, Thermo Fisher) in ABD for 1 h. Cells were washed in PBS and stained with 
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, Vector Laboratories). At least 
300 binucleated cells were scored per group. We tested whether frequency of 
micronuclei differed across groups by using the base package R-function t.test to 
perform Student’s t-test. All statistical analyses were performed in R version 3.6.1 (R 
Core team 2015). 
 
Cell Proliferation Assay 
For cell proliferation assays we used electrical impedance with the xCELLigence 
RTCA DP system from Acea Biosciences. Cells were seeded at a density of 5.0 x 103 
in polyethylene terephthalate (PET) E-plates (300600890, Acea Biosciences). Cells 
were treated with 20 nM MMC or 0.4 µM APH. Electric impedance measurements 
were taken every 15 min for 120 h. We tested whether electric impedance 
measurements differed across timepoints by using the base package R-function t.test 
to perform Student’s t-test. All statistical analyses were performed in R version 3.6.1 
(R Core team 2015).  
 
G2/M Accumulation Assay 
Cells were seeded at a density of 4.0 x 105 in 6 cm2 dishes and treated with 20 nM and 





ice cold methanol. Cells were then washed in PBS and incubated in 0.3-0.5 mL RNase 
solution (1x RNase) for 10 min at 37oC. Cells were then incubated on ice for 5-10 min 
in 50 μg/mL propidium iodide (Sigma). DNA content was measured by 




Table 1. Immuno-precipitation mass spectrometry analysis of FANCD2. 
Protein Peptide Sequence P-site(s) Putative Kinase(s)* 
Previously 
Detected 
FANCD2 R.LS*KSEDKESLTEDASK.T S8 PKACa Yes1 
FANCD2 R.LQDEEAS*M#GASYSK.S S126 RSK2 No 
FANCD2 R.SES*PSLTQER.A S592 P38/MAPK, 
CDK1, CDK2 
Yes2 





FANCD2 K.SQNS*QESTADESEDDM#SSQASK.S S1404 ATR, DNA-PK Yes3 










FANCD2 K.SKATEDGEEDEVS*AGEK.E S1435 CKII, CKI Yes5 
FANCD2 K.ATEDGEEDEVS*AGEK.E S1435 CKII, CKI Yes5 
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Figure 1. FANCD2 is highly phosphorylated under non-stressed conditions and 
during S-phase of the cell cycle 
(A) HeLa, U2OS and COS-7 cells were incubated with or without 200 nM MMC for 
24 h. Cells were harvested and lysed in lambda phosphatase lysis buffer, incubated in 
the absence or presence of lambda phosphatase, and the indicated proteins analyzed 
by immunoblotting. (B) HeLa cells were synchronized at the G1/S boundary by a 
double-thymidine block and then released into thymidine-free media. Cells were 
lysed in lambda phosphatase buffer, incubated in the presence or absence of lambda 
phosphatase, and lysates analyzed by immunoblotting. For cell cycle stage analysis, 
cells were fixed, stained with propidium iodide and analyzed by flow cytometry. Cell 
cycle analysis was performed using FlowJo V10.2 software. (C) FA-A (FANCA-/-) 
and FANCA-complemented FA-A cells were synchronized at the G1/S boundary by a 
double-thymidine block and released into thymidine-free media. Cells were 
harvested, lysed in lambda phosphatase buffer, incubated in the presence or absence 
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Figure 2. FANCD2 is a CDK substrate  
(A) HeLa cells were synchronized at the G1/S boundary by a double-thymidine block 
performed in the absence or presence of the CDK inhibitors Purvalanol A or SNS-032. 
Cells were lysed in lambda phosphatase buffer, incubated in the absence or presence 
of lambda phosphatase, and analyzed by immunoblotting. Cells were also fixed, 
stained with propidium iodide and analyzed by flow cytometry to determine cell cycle 
stage. (B) FA-D2 (FANCD2-/-) cells stably expressing LacZ-V5 or FANCD2-V5 were 
immunoprecipitated with anti-V5 agarose and immune complexes were 
immunoblotted with anti-FANCD2 and anti-pS-CDK antibodies. (C) Purified 
FANCD2 and pRb were incubated in the absence or presence of CDK2/Cyclin A plus 
ATP at 30oC for 30 min. Samples were immunoblotted with a pan anti-pS-CDK 
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Figure 3. FANCD2 is phosphorylated on S592 during S-phase 
(A-B) FANCD2 was immunoprecipitated from U2OS cells stably expressing 
3xFLAG-FANCD2 under stringent conditions using anti-FLAG agarose. Immune 
complexes were analyzed by immunoblotting using anti-FLAG and anti-FANCD2 
antibodies (A), and by staining with SimplyBlue SafeStain (B). Immunoprecipitated 
FANCD2 bands were combined and subjected to phosphoproteomic analysis using 
LC-MS/MS. (C) HeLa cells were synchronized in M-phase by nocodazole block. 
Mitotic cells were harvested or released into nocodazole-free medium for 12 h (S-
phase) prior to harvesting. (D) FANCD2 was immunoprecipitated from M-phase and 
S-phase synchronized cells using an anti-FANCD2 antibody and visualized using 
silver staining (D) or by immunoblotting (E). (F) A schematic of the FANCD2 protein 
indicating phosphorylation sites identified by LC-MS/MS. (G) HeLa cells were 
synchronized in M-phase by a nocodazole block. HeLa FANCD2-/- cells generated by 
CRISPR-Cas9 gene editing (Liang et al. 2016) were used as negative control for 
FANCD2. Immunoblotting was performed with an anti-FANCD2-pS592 antibody, 
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Figure 4. Mutation of S592 disrupts FANCD2 monoubiquitination during S-
phase and following exposure to DNA damaging agents  
(A) Shown is a partial model of the FANCD2 protein illustrating the site of 
monoubiquitination K561 in red and S592 in blue. (B) FA-D2 (FANCD2-/-) patient 
cells stably expressing empty vector or V5-tagged FANCD2-WT, FANCD2-S592A, 
and FANCD2-S592D were incubated in the absence or presence of 200 nM MMC for 
24 h, and whole-cell lysates were analyzed by immunoblotting. (C) FA-D2 cells stably 
expressing empty vector or V5-tagged FANCD2-WT, FANCD2-S592A, or FANCD2-
S592D were synchronized at the G1/S boundary by double-thymidine block. Cells 
were released into thymidine-free medium and whole cell lysates were analyzed by  















































































































































































Figure 5. Mutation of FANCD2 S592 leads to decreased proliferation under 
conditions of replicative stress and increased mitotic defects   
(A) FA-D2 cells stably expressing empty vector or V5-tagged FANCD2-WT, 
FANCD2-S592A, or FANCD2-S592D were incubated in the absence (NT) or 
presence of 0.4 μM aphidicolin (+APH) or 20 nM mitomycin C (+MMC). Cellular 
proliferation was monitored by measuring electrical impedance every 15 minutes over 
a 120 h period using the xCELLigence real time cell analysis system. (B) FA-D2 cells 
were incubated in the presence or absence of 0.4 APH and 40 nM MMC. Then cells 
were treated with Cytochalasin-B for cytokinesis block and stained with DAPI. 
Nucleoplasmic bridges, micronuclei, nuclear buds and multinucleated cells were 
scored. We tested whether frequency of mitotic defects differed across groups by 
using the base package R-function t.test to perform Student’s t-test. All statistical 
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Figure S1. Phosphorylation of FANCD2 during S-phase of the cell cycle 
(A) U2OS cells were synchronized at the G1/S boundary by a double-thymidine 
block and released into thymidine-free media. Cells were harvested, lysed in lambda 
phosphatase buffer and incubated in the presence or absence of lambda phosphatase. 
Samples were analyzed by immunoblotting. (B) Cells were fixed, stained with 
propidium iodide and analyzed by flow cytometry to determine cell cycle stage. (C) 
HeLa cells were synchronized in M-phase with a nocodazole block. Mitotic cells 
were physically detached by the shake-off method and released into nocodazole-free 
media. Cells were harvested, lysed in lambda phosphatase buffer and incubated in the 
presence or absence of lambda phosphatase. Samples were analyzed by 
immunoblotting. (D) Cells were fixed, stained with propidium iodide and analyzed by 
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Figure S2. FANCD2 is a CDK substrate 
(A-B) Shown is an alignment of mouse, human, and chicken FANCD2 (A) and 
FANCI (B) amino acid sequences using the T-Coffee server, with the secondary 
structure of mouse FANCD2 or FANCI illustrated. Putative CDK phosphorylation 
sites are shaded in yellow. (C) HeLa cells were incubated in the absence or presence 
of 10 μM olumucine, 10 μM olomucine II, 10 μM purvalanol A, 10 μM RO3306 and 
20 μM roscovitine for 24 h. Whole cell lysates were incubated in the absence or 
presence of lambda phosphatase and analyzed by immunoblotting. (D) HeLa cells 
were treated with 10 μM purvalanol A for the indicated times, lysates were incubated 















DAPI H3 pS10 Merge















- - +     - - +           MMC














































































































































































































































































































Figure S3. Mutation on S592 affects cell cycle progression / Cells lacking 
FANCD2 exhibit increased mitotic arrest in unstressed conditions 
(A) Wild-type HeLa and HeLa FANCD2-/- cells generated by CRISPR-Cas9 gene 
editing were incubated in the absence or presence of 100 nM MMC for 24 h. Cells 
were fixed and co-immunofluoresence microscopy was performed for FANCD2 
(green) and H3 pS10 (red). (B) The same cells were treated with 100 nM MMC or 1 
mM acetaldehyde for 24 h and whole-cell lysates analyzed by immunoblotting. (C) 
Cells were incubated in the absence or presence of 100 nM MMC or 0.2 μM APH for 
24 h. Cells were fixed, stained with propidium iodide and analyzed by flow cytometry. 
Cell cycle stage analysis was performed using the FlowJo V10.2 software. (D) FA-D2 
cells stably expressing empty vector or V5-tagged FANCD2-WT, FANCD2-S592A, 
or FANCD2-S592D were synchronized at the G1/S boundary by double-thymidine 
block, and then released into thymidine-free medium. At the indicated time points, 
cells were fixed, stained with propidium iodide and analyzed by flow cytometry. Cell 
cycle stage analysis was performed using the FlowJo V10.2 software. (E)  FA-D2 cells 
stably expressing empty vector or V5-tagged FANCD2-WT, FANCD2-S592A, or 
FANCD2-S592D were treated with 20 nM and 40 nM MMC for 24 h and 48 h. Cells 
were fixed with methanol, stained with propidium iodide and analyzed by flow 











NT 30 h 60 h 90 h 120 h
E-WT 0.038 0.084 0.066 0.131
E-SA 0.014 0.015 0.011 0.015
E-SD 0.913 0.292 0.061 0.053
WT-SA 0.448 0.022 0.002 0.005
WT-SD 0.064 0.363 0.811 0.296
SA-SD 0.249 0.035 0.070 0.228
0.4 µM 
APH
30 h 60 h 90 h 120 h
E-WT 0.359 0.377 0.088 0.015
E-SA 0.524 0.969 0.632 0.273
E-SD 0.976 0.786 0.490 0.465
WT-SA 0.116 0.176 0.029 0.025
WT-SD 0.045 0.053 0.034 0.019
SA-SD 0.389 0.625 0.724 0.635
20 nM
MMC
30 h 60 h 90 h 118 h
E-WT 0.034 0.072 0.010 0.0004
E-SA 0.021 0.021 0.001 0.002
E-SD 0.009 0.173 0.003 0.006
WT-SA 0.923 0.935 0.214 0.096
WT-SD 0.085 0.177 0.280 0.052



















0 30 60 90 120 150
NT 30 h 60 h 90 h 120 h 140 h
E-WT 0.645 0.492 0.852 0.938 0.505
E-SA 0.265 0.059 0.027 0.135 0.152
E-SD 0.859 0.979 0.871 0.838 0.907
WT-SA 0.286 0.111 0.059 0.114 0.077
WT-SD 0.884 0.616 0.768 0.752 0.360
SA-SD 0.265 0.048 0.062 0.076 0.150
2 µM 
RO3306
30 h 60 h 90 h 120 h 140 h
E-WT 0.340 0.132 0.125 0.088 0.033
E-SA 0.006 0.026 0.016 0.020 0.007
E-SD 0.889 0.604 0.381 0.890 0.542
WT-SA 0.419 0.431 0.256 0.316 0.297
WT-SD 0.402 0.092 0.075 0.107 0.091



















Figure S4. Mutation of FANCD2 S592 leads to decreased proliferation under 
conditions of replicative stress 
(A) FA-D2 cells stably expressing empty vector or V5-tagged FANCD2-WT, 
FANCD2-S592A, or FANCD2-S592D were incubated in the absence (NT) or 
presence of 0.4 μM aphidicolin (+APH) or 20 nM mitomycin C (+MMC). Cellular 
proliferation was monitored by measuring electrical impedance every 15 minutes over 
a 120 h period using the xCELLigence real time cell analysis system. Student’s t-test 
was used to compare the means of electrical impedance measurements between 
populations at 30 h, 60 h, 90 h and 120 h. (B) The same cells were incubated in the 
absence or presence of 2 μM RO3306 and cellular proliferation was monitored by 
measuring electrical impedance every 15 minutes over a 140 h period using the 
xCELLigence real time cell analysis system. (C) Student’s t-test was used to compare 
electrical impedance measurements between populations at 30 h, 60 h, 90 h, 120 h, 









































































































































































T-test NT + CytB MMC + CytB APH + CytB
Empty-WT 0.067 0.182 0.008
Empty-K561R 0.933 0.0003 0.001
Empty-S592A 0.126 0.041 0.008
Empty-S592D 0.413 0.148 0.053
WT-K561R 0.090 0.035 0.589
WT-S592A 0.001 0.517 0.942
WT-S592D 0.009 0.989 0.449
K561R-S592A 0.115 0.140 0.510
K561R-S592D 0.377 0.016 0.182



















T-test NT + CytB MMC + CytB APH + CytB
Empty-WT 0.526 0.412 0.060
Empty-K561R 0.244 0.633 0.370
Empty-S592A 0.305 0.003 0.004
Empty-S592D 0.047 0.088 0.091
WT-K561R 0.543 0.246 0.301
WT-S592A 0.632 0.051 0.187
WT-S592D 0.140 0.465 0.890
K561R-S592A 0.920 0.003 0.030
K561R-S592D 0.439 0.056 0.393

















T-test NT + CytB MMC + CytB APH + CytB
Empty-WT 0.011 0.040 0.945
Empty-K561R 0.333 0.040 0.627
Empty-S592A 0.456 0.899 0.200
Empty-S592D 0.164 0.219 0.119
WT-K561R 0.099 0.929 0.638
WT-S592A 0.163 0.058 0.304
WT-S592D 0.244 0.002 0.213
K561R-S592A 0.960 0.579 0.089
K561R-S592D 0.644 0.002 0.046


















T-test NT + CytB MMC + CytB APH + CytB
Empty-WT 0.00107 0.0755 0.2683
Empty-K561R 0.2759 0.642 0.5814
Empty-S592A 0.09614 0.8163 0.2553
Empty-S592D 0.07672 0.675 0.2796
WT-K561R 0.01768 0.02605 0.4518
WT-S592A 0.08317 0.06528 0.9826
WT-S592D 0.202 0.2437 0.9641
K561R-S592A 0.5319 0.8483 0.4354
K561R-S592D 0.4116 0.4066 0.473







Figure S5. Mutation in S592 causes increased mitotic aberrations 
(A) FA-D2 cells were incubated in the presence or absence of 0.4 aphidicolin (APH) 
and 40 nM mitomycin C (MMC). Then cells were treated with cytochalasin-B for 
cytokinesis block and stained with DAPI (B). Nucleoplasmic bridges were scored in 
300 binucleated cells. (C) Micronuclei were scored in at least 300 binucleated cells. 
(D) Nuclear buds were scored in at least 400 cells. (E) Cells with more than 2 nuclei 
were scored. We tested whether frequency of mitotic defects differed across groups by 
using the base package R-function t.test to perform Student’s t-test. All statistical 































































Figure S6. Mutation in S592 causes increased mitotic aberrations during non-
stressed conditions.  
FA-D2 cells were incubated without the presence of DNA damaging agents. Then 
cells were fixed in ice cold methanol and stained with DAPI. Binucleated, 
micronuclei, nuclear buds and multinucleated cells were scored. We tested whether 
frequency of mitotic defects (A-Binucleated, B- Nuclear Buds, C- Micronuclei, D- 
Multinucleated) differed across groups by using the base package R-function t.test to 
perform Student’s t-test. All statistical analyses were performed in R version 3.6.1 (R 
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